Evidence map›Paper›PMID 26618550›Full record

Trial reportBone marrow transplantation2016

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

S P Robinson, A Boumendil, H Finel, D Blaise, X Poiré, E Nicolas-Virelizier, R Or, R Malladi, A Corby, L Fornecker and 10 more

Open access · greenAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 7 countries.

S P RobinsonDepartment of Haematology, University Hospital Bristol NHS Foundation Trust, Bristol, UK.
A BoumendilLymphoma Working Party, EBMT, Paris, France.
H FinelLymphoma Working Party, EBMT, Paris, France.
D BlaiseProgram de Transplantation and Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France.
X PoiréDepartment of Haematology, Cliniques Universitaires St. Luc, Brussels, Belgium.
E Nicolas-VirelizierDepartment of Haematology, Centre Leon Berard, Lyon, France.
R OrDepartment of BMT, Hadassah University Hospital, Jerusalem, Israël.
R MalladiDepartment of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
A CorbyServices des Maladies du Sang, CHU, Angers, France.
L ForneckerDepartment of Haematology, Nouvel Hopital Civil, Strasbourg, France.
D CaballeroServicio de Haematogica, Hospital Clínico, Salamanca, Spain.
D PohlreichDepartment of Medicine, Charles University Hospital, Prague, Czech Republic.
A NaglerDepartment of Haematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
C ThieblemontAPHP Hemato-Oncology Department, Saint-Louis Hospital, Paris, France.
J FinkeDepartment of Medicine, University of Freiburg, Germany.
E BachyDepartment of Haematology, Hospices Civils de Lyon, Pierre-Benite, France.ORCID http://orcid.org/0000-0003-2694-7510
L VincentDepartment d'Hematologie Clinique, CHU Lapeyronie, Montpellier, France.ORCID http://orcid.org/0000-0001-5904-1286
W SchroyensDepartment of Haematology, Antwerp University Hospital (UZA), Antwerp Edegem, Belgium.
H SchoutenDepartment of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.
P DregerMedizinische Klinik, University Of Heidelberg, Heidelberg, Germany.
European Society for Blood and Marrow Transplantation · FRAntwerp University Hospital · BEAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire d'Angers · FRCentre Léon Bérard · FRCharles University · CZCliniques Universitaires Saint-Luc · BEHadassah Academic College · ILHôpital Civil, Strasbourg · FRHôpital Lapeyronie · FRHospices Civils de Lyon · FRInstitut Paoli-Calmettes · FRMaastricht University Medical Centre · NLQueen Elizabeth Hospital Birmingham · GBSheba Medical Center · ILUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.

Indexed as

Stem Cell TransplantationAdolescentAdultAgedAutograftsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedRecurrenceRituximabSurvival RateRituximab

Identifiers

PMID26618550
OpenAlexW2179179262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.